Bayer/J&J contemplate edge of the earth in VTE as MAGELLAN scuppers Xarelto
This article was originally published in Scrip
Executive Summary
Bayer and Johnson & Johnson's attempts the circumnavigate the world of venous thromboembolism (VTE) prevention with their oral Factor Xa inhibitor Xarelto (rivaroxaban) have hit an unexpected setback in the MAGELLAN study of medically ill patients.